All In Biotech

Drug Trial Radar · NCT06366490

Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer

Phase 1 Study to Assess the Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy Administered in Patients With Recurrent Epithelial Ovarian Cancer

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Feb 12, 2026

Primary completion

Nov 2028

Study completion Dec 2028

Sponsor

Lead sponsor
PhotonPharma, Inc.Industry
Sponsor type
Industry
First posted
Apr 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1 study to evaluate the safety and immunogenicity of Innocell, an autologous cellular immunotherapy made from patient-derived tumor cells, in female patients with recurrent epithelial ovarian cancer. Innocell autologous cellular immunotherapy consists of autologous tumor cells which have been inactivated using a proprietary light technology that inhibits cell replication while allowing for the cell to maintain antigen expression. These replication incompetent cells are then administered concurrently with an immunoadjuvant to stimulate a person's innate or adaptive immune response to vaccine antigens. This novel inactivation mechanism creates improved antigen presentation, specifically with presentation of the broad array of neoantigens unique to each patient's tumor.

Conditions

  • Ovarian Cancer (OvCa)

Interventions

  • InnocellBiological

    Innocell an autologous immunotherapy + CpG 1018 adjuvant

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Success rate of autologous manufacturingTime frame: Approximately 2 months from Enrollment to Manufacturing release
  2. Safety assessed by treatment emergent adverse eventsTime frame: From enrollment until 30 days after the last dose of Innocell

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.